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Summary		
Understanding	 the	 circuits	 that	 promote	 an	 efficient	 resolution	 of	 inflammation	 is	 crucial	 to	
deciphering	 the	molecular	 and	 cellular	 processes	 required	 to	 promote	 tissue	 repair.	Macrophages	
play	 a	 central	 role	 in	 the	 regulation	 of	 inflammation,	 resolution	 and	 repair/regeneration.	 Using	 a	
model	 of	 skeletal	 muscle	 injury	 and	 repair,	 herein	 we	 identify	 Annexin	 A1	 (AnxA1)	 as	 the	
extracellular	trigger	of	macrophage	skewing	towards	a	pro-reparative	phenotype.	Brought	 into	the	
injured	tissue	initially	by	migrated	neutrophils,	and	then	over-expressed	in	infiltrating	macrophages,	
AnxA1	 activates	 FPR2/ALX	 receptors	 and	 the	 downstream	 AMPK	 signalling	 cascade	 leading	 to	
macrophage	 skewing,	dampening	of	 inflammation	and	 regeneration	of	muscle	 fibres.	Mice	 lacking	
AnxA1	 in	 all	 cells	 or	 in	 myeloid	 cells	 only	 display	 a	 defect	 in	 this	 reparative	 process.	 In	 vitro	
experiments	 recapitulated	 these	properties,	with	AMPK	null	macrophages	 lacking	AnxA1-mediated	
polarization.	 Collectively,	 these	 data	 identify	 the	 AnxA1/FPR2/AMPK	 axis	 as	 a	 novel	 pathway	 in	
skeletal	muscle	injury	regeneration.	
	
Keywords:	macrophage	switch,	resolution	of	inflammation,	skeletal	muscle	homeostasis	
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Introduction		
An	efficient	inflammatory	response	is	a	necessary	component	of	the	reaction	to	injury	or	infection,	
but	it	is	equally	critical	for	this	inflammatory	response	to	be	terminated	in	a	timely	and	appropriate	
manner,	enabling	the	restoration	of	tissue	homeostasis	(Perretti	et	al.,	2017;	Serhan,	2014).	Indeed,	
chronic	inflammation	that	results	from	failure	of	resolution	represents	a	major	contributing	factor	to	
a	 multitude	 of	 pathologies,	 from	 arthritis	 to	 sepsis	 to	 dementia	 (Perretti	 et	 al.,	 2015;	 Tabas	 and	
Glass,	2013).		
	
An	 inflammatory	 reaction	 consists	 of	 the	 co-ordinated	 activity	 of	 numerous	 cells	 and	 soluble	
mediators,	but	a	central	role	is	played	by	macrophages.	These	cells,	whether	resident	in	the	tissue	or	
recruited	from	circulating	monocyte	populations,	are	amongst	the	first	responders	to	pathogen-	or	
damage-associated	molecular	patterns,	 initiating	endothelial	activation	and	neutrophil	 recruitment	
(Davies	and	Taylor,	2015).	Beyond	their	roles	as	sentinels,	macrophages	are	important	drivers	of	the	
progression	 of	 an	 inflammatory	 response,	 acting	 to	 clear	 pathogens,	 effete	 cells	 and	 debris	 by	
phagocytosis	(Mantovani	et	al.,	2013),	serving	as	antigen	presenting	cells	to	recruit	the	adaptive	arm	
of	 the	 immune	 response	 (Motwani	 and	Gilroy,	 2015),	 and	 ultimately	 enabling	 processes	 of	 tissue	
repair	and	resolution	(Lucas	et	al.,	2010;	Troidl	et	al.,	2009).	That	one	cell	type	is	able	to	achieve	this	
diverse	 array	of	 functions	 is	 due	 in	 large	part	 to	 their	 remarkable	degree	of	 phenotypic	plasticity,	
with	macrophages	existing	in	a	wide	variety	of	forms	along	a	spectrum	running	from	a	largely	pro-
inflammatory	 state,	 often	 indicated	 as	 M1,	 to	 a	 primarily	 non-phlogistic	 and	 pro-resolving	
phenotype,	termed	M2	(Murray	et	al.,	2014).		
	
A	 number	 of	 factors	 promoting	 this	 phenotypic	 transformation	 have	 been	 studied	 including	
exposure	 to	 anti-inflammatory	 cytokines	 such	 as	 interleukin	 (IL)-10	 and	 IL-4,	 and	 the	 phagocytic	
removal	 of	 cell	 debris,	 although	 a	 complete	 description	 of	 the	 underlying	 mechanisms	 is	 lacking	
(Martinez	and	Gordon,	2014).	We	and	others	have	identified	a	key	role	for	the	intracellular	signalling	
pathway	governed	by	AMP-activated	protein	kinase	(AMPK)	(Chan	et	al.,	2015;	Mounier	et	al.,	2013;	
Park	 et	 al.,	 2017).	 Activation	 of	 this	 pathway	 is	 required	 for	 efficient	 conversion	 of	 pro-	 to	 anti-
inflammatory-type	macrophages,	and	inhibition	of	such	a	response	significantly	attenuated	recovery	
in	 a	 model	 of	 inflammatory	 skeletal	 muscle	 injury	 (Mounier	 et	 al.,	 2013).	 Whilst	 AMPK	 is	
undoubtedly	 important	 in	 the	 phenotypic	 conversion	 of	 macrophages	 during	 the	 course	 of	 an	
inflammatory	reaction,	the	nature	of	the	extracellular	trigger(s)	for	its	stimulation	remain	unclear.		
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The	protein	annexin	A1	(ANXA1)	 (Lim	and	Pervaiz,	2007;	Perretti	and	D'Acquisto,	2009),	 is	a	major	
driver	 of	 inflammatory	 resolution,	 promoting	 neutrophil	 apoptosis	 (Solito	 et	 al.,	 2003),	 non-
phlogistic	monocyte	recruitment	(McArthur	et	al.,	2015)	and	macrophage	efferocytosis	(Dalli	et	al.,	
2012;	 Scannell	 et	 al.,	 2007).	 Moreover,	 we	 and	 others	 have	 recently	 provided	 evidence	 showing	
ANXA1	 to	promote	an	anti-inflammatory	macrophage	phenotype	 in	 in	vitro	models	of	 rheumatoid	
arthritis	(Rhys	et	al.,	2018)	and	tumour	growth	(Moraes	et	al.,	2017),	but	how	this	translates	to	an	in	
vivo	situation	is	less	clear.	Against	this	background,	we	applied	a	well-characterised	model	of	skeletal	
muscle	injury	(Arnold	et	al.,	2007;	Varga	et	al.,	2013;	Varga	et	al.,	2016a)	to	test	the	hypothesis	that	
ANXA1	and	its	receptor	FPR2/ALX	could	be	the	upstream	trigger	of	AMPK	activation,	and	hence	be	a	
major	driver	of	the	pro-	to	anti-inflammatory	macrophage	phenotype	shift,	promoting	inflammatory	
resolution	and	the	restoration	of	skeletal	muscle	tissue	homeostasis.		
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Results		
	
Annexin	A1	and	Fpr2/3	null	mice	show	impaired	recovery	from	skeletal	muscle	injury	
To	investigate	the	role	of	ANXA1	and	its	receptor	FPR2/ALX	(in	humans,	or	the	orthologue	Fpr2/3	in	
mice)	 in	 the	 control	 of	macrophage	 phenotype	we	 first	 utilised	 the	murine	model	 of	 cardiotoxin-
induced	Tibialis	Anterior	(TA)	injury,	a	model	characterised	by	necrotic	tissue	damage	and	extensive	
macrophage	activity	(d'Albis	et	al.,	1988;	Mounier	et	al.,	2013).	Analysis	of	immune	cell	infiltration	in	
lesioned	wild-type	mice	revealed	a	typical	inflammatory	profile,	dominated	by	Ly6G+	neutrophils	for	
the	initial	post-lesioning	period,	supplanted	by	F4/80+	macrophages	from	day	2	onwards	(Suppl	Fig	
1A-B).	Monitoring	ANXA1	expression	in	the	tissue	revealed	that	while	absent	in	uninjured	tissue,	the	
protein	was	primarily	restricted	to	immune	cells	until	day	2	post-lesioning,	with	regenerating	muscle	
fibres	displaying	weak	immunostaining	from	Day	7	(Suppl	Fig	1A-B),	as	reported	previously	(Bizzarro	
et	al.,	2012).	Whilst	F4/80+	murine	macrophages	expressed	AnxA1	at	all	time-points	examined	(Suppl	
Fig	 1B-C),	 the	proportion	of	macrophages	 expressing	 its	 primary	 receptor,	 Fpr2/3,	 decreased	over	
time,	from	approximately	95%	at	day	2	to	70%	at	day	7	and	just	5%	two	weeks	post-lesioning,	even	
though	 significant	 numbers	 of	 macrophages	 were	 still	 detected	 in	 the	 tissue	 (Suppl	 Fig	 2A-B).	
Importantly,	 expression	 of	 Fpr2/3	 on	muscle	 fibers	was	 not	 apparent	 at	 any	 time-point	 examined	
(Suppl	Fig	2A).	
	
Whilst	uninjured	TA	muscle	weights	were	comparable	between	wild-type,	AnxA1-/-	and	Fpr2/3-/-	mice	
(Fig	 1A-B,	 Suppl	 Fig	 3A),	 recovery	 of	 muscle	 mass	 following	 administration	 of	 cardiotoxin	 was	
significantly	 reduced	 in	 AnxA1-/-	 and	 Fpr2/3-/-	mice	 than	 in	wild-type	 animals	 (Fig	 1B).	 Histological	
analysis	of	muscles	28	days	post-injury	revealed	significantly	reduced	myofiber	cross-sectional	area	
(CSA)	and	myonuclei	per	 fiber	 (i.e.	 the	 result	of	differentiation	and	 fusion	of	muscle	 stem	cells)	 in	
AnxA1-/-	and	Fpr2/3-/-	animals	(Fig	1C-E).	These	outcomes	are	suggestive	of	impaired	skeletal	muscle	
regeneration,	a	notion	confirmed	by	marked	lipid	accumulation	in	AnxA1-/-	mice	(Fig	1F).	Analysis	of	
immune	cell	infiltration	by	flow	cytometry	revealed	that	2	days	following	cardiotoxin	administration,	
approximately	 60%	 of	 macrophages	 expressed	 a	 pro-resolving,	 anti-inflammatory	 phenotype	
(CD45+Ly6C/GnegF4/80hi)	in	wild-type	mice,	whilst	AnxA1-/-	and	Fpr2/3-/-	animals	showed	comparable	
levels	of	pro-	 (CD45+Ly6C/GhiF4/80low)	 and	anti-inflammatory	 (CD45+Ly6C/GlowF4/80hi)	 cells	 (Fig	1G,	
Suppl	Fig	3B).	Consequently,	the	resolution	 index	(ratio	of	anti-	to	pro-inflammatory	macrophages)	
of	AnxA1-/-	and	Fpr2/3-/-	mice	was	significantly	 lower	than	that	of	wild-type	animals,	 indicative	of	a	
prolonged	 inflammatory	 response	 (Fig	 1H).	 These	 results	 indicate	 that	 a	 proportion	 of	 pro-
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inflammatory	 macrophages	 fail	 to	 convert	 to	 an	 anti-inflammatory	 phenotype	 at	 the	 time	 of	
resolution	in	the	absence	of	AnxA1	or	Fpr2/3.	
	
Macrophages	are	the	major	source	of	AnxA1	in	lesion	recovery	
The	more	pronounced	effects	of	cardiotoxin	in	AnxA1-/-	and	Fpr2/3-/-	mice	indicate	the	existence	of	
important	 regulatory	 functions	 for	 this	 pathway	 in	 skeletal	 muscle	 injury.	 However,	 while	 Fpr2/3	
expression	 appears	 restricted	 to	 immune	 cells	 infiltrating	 the	 TA	 muscle	 (Suppl	 Fig	 2),	 AnxA1	 is	
expressed	markedly	by	immune	cells	and	to	a	lower	extent	by	regenerating	muscle	fibres	(Suppl	Fig	
1).	As	such,	we	deemed	it	important	to	define	the	primary	cell	source	of	this	mediator	in	the	repair	
process,	a	question	we	addressed	using	chimeric	mice	bearing	wild-type	muscle	but	AnxA1-/-	bone	
marrow-derived	 leukocytes.	 Therefore,	 CX3CR1-GFP	 mice,	 which	 harbour	 GFP-expressing	
monocytes/macrophages	were	irradiated	and	transplanted	with	wild-type	or	AnxA1-/-	derived	bone	
marrow	cells,	 prior	 to	 injection	of	 cardiotoxin	 in	 the	TA	muscle	 (Fig	2A).	Analysis	of	bone	marrow	
populations	at	the	time	of	euthanasia	showed	less	than	1%	of	monocytes	(CD115pos	cells)	expressed	
GFP,	suggesting	>99%	engraftment	efficiency	with	either	wild-type	or	AnxA1-/-	bone	marrow	(Fig	2B-
C).	Weight	recovery	was	similar	after	wild-type	or	AnxA1-/-	transplant	(Suppl	Fig	3C),	but	histological	
analysis	of	TA	muscles	28-days	post-CTX	injury	revealed	that	animals	receiving	AnxA1-/-	bone	marrow	
cells	displayed	a	significantly	reduced	myofiber	cross-sectional	area	than	animals	receiving	wild-type	
bone	 marrow	 cells	 (Fig	 2D-E).	 These	 data	 indicate	 that	 the	 defective	 regeneration	 quantified	 in	
AnxA1-/-	muscle	is	a	consequence	of	an	intrinsic	defect	in	myeloid,	rather	than	stromal,	cells.	
	
Exogenous	ANXA1	can	induce	human	macrophage	phenotype	conversion	in	vitro	
As	our	murine	analyses	indicate	a	potential	role	for	AnxA1	in	the	polarization	of	macrophages	from	a	
pro-inflammatory	 to	 a	 pro-resolving/reparative	 phenotype,	 we	 investigated	 these	 effects	 in	 vitro	
using	human	PBMC-derived	macrophages.	An	M1-like	macrophage	phenotype	was	induced	by	24	h	
incubation	with	bacterial	lipopolysaccharide	(LPS)	and	γ-interferon	(IFNγ),	prior	to	addition	of	human	
recombinant	 ANXA1	 (hrANXA1).	 Following	 hrANXA1	 treatment,	 analysis	 of	 cell	 surface	 markers	
revealed	 a	 significant	 reduction	 in	 expression	 of	 the	M1	marker	 protein	major	 histocompatibility	
complex	 II	 (MHCII)	 (Fig	3A),	accompanied	by	a	significant	 increase	 in	expression	of	 the	M2	marker	
protein	 CD206	 (Fig	 3B).	 These	 surface	 marker	 changes	 were	 mirrored	 by	 changes	 at	 the	
transcriptional	level,	with	hrANXA1	treatment	inducing	a	reduction	in	mRNA	expression	for	the	pro-
inflammatory	species	Tnfa	and	Nos2	paired	with	increased	message	of	Il-10	(Fig.	3C-E).	No	significant	
changes	 in	Tgfb1	expression	were	quantified	 (Fig.	3F).	Together,	 these	 in	vitro	data	support	our	 in	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 7	
vivo	 findings,	 providing	 evidence	 that	 ANXA1	 application	 favours	 a	 pro-resolving	 macrophage	
phenotype.		
	
The	 specificity	 of	 hrANXA1	 action	 through	 its	 human	 receptor	 FPR2/ALX	was	 then	determined,	 to	
complement	the	in	vivo	observations	made	with	Fpr2/3-/-	mice	lacking	the	orthologue	of	the	human	
FPR2/ALX	 (Dufton	 et	 al.,	 2010).	 Intriguingly,	 we	 observed	 significant	 FPR2/ALX	 surface	 expression	
both	 in	unstimulated	human	PBMC-derived	macrophages	and	M1-phenotype	cells,	yet	cell	 surface	
expression	of	 the	receptor	was	 lost	on	cells	stimulated	towards	an	M2	phenotype	with	 IL-4	 (Suppl	
Fig.	 4).	 These	 data	 are	 in	 agreement	 with	 the	 in	 vivo	 observation	 that	 Fpr2/3-/-	 is	 absent	 from	
macrophages	 that	 have	 infiltrated	 the	 injured	 muscle	 at	 Day	 7	 and	 beyond,	 that	 is,	 when	 a	
reparative	 cell	 phenotype	 has	 been	 acquired	 (Suppl	 Fig	 2B-C).	 The	 functional	 engagement	 of	
FPR2/ALX	 was	 then	 confirmed	 through	 use	 of	 the	 selective	 antagonist	 WRW4.	 The	 modulatory	
effects	 of	 hrANXA1	 on	 pro-inflammatory	 PBMC-derived	macrophages	 (i.e.	 reduced	 surface	MHCII	
expression	and	augmented	surface	CD206	expression)	were	lost	in	the	presence	of	WRW4	(Fig.	3G-
H).		
	
Together	 these	 experiments	 represent	 a	 clear	 in	 vitro	 counterpart	 to	 the	 effects	 observed	 in	 the	
muscle	 injury	model,	 showing	 the	 key	 role	 of	 ANXA1	 acting	 through	 FPR2/ALX	 to	 drive	 a	 shift	 in	
macrophage	phenotype	towards	a	pro-resolving	and	reparative	polarization.		
	
Exogenous	ANXA1	treatment	stimulates	AMPK	activation	through	FPR2/ALX	
The	 enzyme	 5'-adenosine	monophosphate-activated	 protein	 kinase,	 AMPK,	 plays	 a	 critical	 role	 in	
macrophage	 phenotype	 skewing	 and	 is	 necessary	 for	 efficient	 regeneration	 after	 skeletal	 muscle	
damage	 (Mounier	 et	 al.,	 2013).	 We	 queried	 whether	 this	 signalling	 pathway	 would	 underlie	 the	
effects	of	hrANXA1	upon	human	macrophage	phenotype	and	indeed	muscle	repair	in	vivo.	
	
Exposure	of	human	PBMC-derived	macrophages	to	hrANXA1	activated	a	number	of	components	of	
the	 AMPK	 signalling	 pathway,	 promoting	 phosphorylation	 of	 Ca2+/calmodulin-dependent	 protein	
kinase	II,	AMPKα1	itself	and	its	downstream	effector	acetyl-CoA	carboxylase	(Fig	4A-B).	Interestingly,	
the	 phosphorylation	 of	 these	 proteins	 in	 macrophages	 only	 occurred	 to	 an	 appreciable	 degree	
following	exposure	to	hrANXA1	for	30-60	min	(Fig	4B-D),	 in	contrast	to	early	MAP	kinase	signalling	
previously	 reported	 in	 human	 monocytes	 (McArthur	 et	 al.,	 2015).	 That	 activation	 of	 AMPKα1	
depended	upon	binding	of	hrANXA1	to	FPR2/ALX	was	confirmed	through	analysis	of	 the	effects	of	
the	 antagonist	 WRW4,	 which	 abrogated	 hrANXA1-evoked	 AMPKα1	 phosphorylation	 in	 human	
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macrophages	 (Fig	 4E).	Analyses	of	murine	bone	marrow-derived	macrophages	 from	wild-type	and	
Fpr2/3-/-	animals	confirmed	the	pivotal	role	of	this	receptor:	whilst	treatment	with	hrANXA1	induced	
phosphorylation	 of	 AMPKα1	 in	 wild-type	 cells,	 this	 response	 was	 absent	 in	 macrophages	 from	
Fpr2/3-/-	mice	(Fig	4F).	
	
AMPK	activation	is	required	for	macrophage	phenotype	conversion	induced	by	ANXA1	
We	 investigated	 the	 relationship	 between	 FPR2/ALX-mediated	 AMPK	 activation	 and	 the	 shift	 in	
macrophage	phenotype	induced	by	hrANXA1	treatment	through	analyses	in	primary	bone	marrow-
derived	macrophages	taken	from	wild-type	mice	and	animals	lacking	the	key	catalytic	α1	subunit	of	
AMPK	 (Jorgensen	 et	 al.,	 2005).	Whilst	 treatment	 of	wild-type	macrophages	with	 hrANXA1	 (10nM,	
24h)	reduced	the	percentage	of	macrophages	positive	 for	 the	pro-inflammatory	markers	 iNOS	and	
CCL3,	 this	 response	 was	 notably	 absent	 in	 cells	 from	 AMPKα1-/-	 mice	 (Fig	 5A).	 Correspondingly,	
hrANXA1	treatment	augmented	 the	proportion	of	wild	 type	cells	expressing	 the	anti-inflammatory	
markers	TGFβ1	(notably	at	variance	from	human	macrophages),	CD163	and	CD206,	but	this	did	not	
occur	in	cells	lacking	AMPKα1	(Fig	5B).	Together,	these	data	indicate	activation	of	AMPKα1	as	a	key	
step	in	the	macrophage	phenotype	shift	induced	by	ANXA1.		
	
To	confirm	these	findings	in	human	cells,	we	employed	an	RNA	interference	approach,	transfecting	
primary	 PBMC-derived	 macrophages	 with	 three	 distinct	 siRNA	 constructs	 targeting	 the	 AMPKα1	
subunit	 (Fig.	5C).	Treatment	of	M1-like	pro-inflammatory	macrophages	 for	6	h	with	10	nM	ANXA1	
reduced	expression	of	MHCII	and	augmented	CD206	in	mock	transfected	cells	and	in	cells	bearing	a	
non-targeting	siRNA	construct;	this	effect	was	absent	in	cells	transfected	with	any	of	three	different	
siRNA	constructs	targeting	human	AMPKα1	(Fig.	5D-E).		
	
Adult	myogenesis	is	ANXA1-AMPK	signalling	dependent	in	vitro	
Together,	 these	 data	 from	 human	 and	 mouse	 macrophages	 make	 a	 compelling	 case	 that	
macrophage	 phenotype	 shifting	 can	 be	 induced	 through	 an	 ANXA1/FPR2/AMPK	 cascade.	 To	
investigate	whether	this	process	underlies	differences	in	recovery	from	cardiotoxin-induced	muscle	
lesions	 seen	 between	 wild-type	 and	 AnxA1-/-	 and	 Fpr2/3-/-	 mice,	 we	 made	 use	 of	 an	 established	
model	of	in	vitro	muscle	repair	(Mounier	et	al.,	2013;	Varga	et	al.,	2016b).		
	
We	 employed	 an	 in	 vitro	model	 of	 adult	myogenesis	 in	which	 conditioned	medium	 from	 primary	
bone	 marrow-derived	 macrophages	 was	 used	 to	 stimulate	 primary	 murine	 myoblasts	 for	 72h,	
quantifying	 the	 proportion	 of	 multinucleated	 myotubes	 (Fig.	 5F).	 As	 such	 this	 in	 vitro	 setting	
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recapitulates	the	processes	of	adult	myogenesis	(activation,	differentiation,	migration	and	fusion	of	
muscle	 cells)	 that	 occur	 during	 skeletal	 muscle	 regeneration	 (Mounier	 et	 al.,	 2013;	 Varga	 et	 al.,	
2016b).	 Conditioned	medium	 from	 ANXA1-treated	wild-type	macrophages	 induced	 an	 increase	 in	
myotube	 fusion	 index	 (Fig	 5G-I).	 This	 response	 was	 absent	 when	 myotubes	 were	 treated	 with	
conditioned	medium	from	ANXA1-treated	AMPKα1-/-	macrophages	(Fig	5G-I).		
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Discussion	
The	 timely	 resolution	 of	 inflammation	 is	 a	 fundamental	 requirement	 for	 restoring	 homeostasis	
following	 infection	or	 damage,	with	 its	 failure	 being	 a	 significant	 contributory	 factor	 to	 numerous	
chronic	inflammatory	pathologies.	Macrophages	are	key	players	in	this	process,	given	their	ability	to	
transition	 from	generally	pro-inflammatory	 to	anti-inflammatory	phenotypes	 (Motwani	and	Gilroy,	
2015).	 Substantial	 effort	has	 gone	 into	deciphering	 the	 complex	 signals	underpinning	macrophage	
plasticity,	with	numerous	 soluble	mediators	having	been	 implicated	 (Martinez	and	Gordon,	2014),	
but	 the	 mechanistic	 link	 between	 these	 factors	 and	 changes	 in	 phenotype	 remains	 poorly	
understood	especially	when	 investigated	 in	 specific	 tissue-restricted	 settings.	 In	 the	current	 study,	
we	 have	 employed	 a	 well-characterised	 model	 of	 muscular	 injury	 and	 recovery	 (Mounier	 et	 al.,	
2013)	 to	 identify	 the	 ability	 of	 myeloid	 cell-derived	 ANXA1	 to	 promote	 an	 anti-inflammatory	
macrophage	phenotype,	promoting	resolution	and	tissue	repair.	Moreover,	we	show	the	actions	of	
this	protein	to	be	mediated	through	the	cell	surface	receptor	FPR2/ALX	and	consequent	activation	of	
the	 intracellular	 signalling	 molecule	 AMPK,	 mechanistically	 linking	 external	 and	 intracellular	 pro-
resolving	signals	governing	macrophage	phenotype.		
	
These	 data	 reinforce	 the	 status	 of	 the	 ANXA1-FPR2/ALX	 pair	 as	 a	 major	 endogenous	 driver	 of	
inflammatory	resolution,	and	add	to	its	known	roles	in	regulating	neutrophil	apoptosis	(Solito	et	al.,	
2003),	efferocytosis	(Maderna	et	al.,	2005;	Scannell	et	al.,	2007),	and	the	recruitment	of	monocytes	
to	 inflammatory	sites	(Gobbetti	et	al.,	2014;	McArthur	et	al.,	2015).	Notably,	despite	muscle	tissue	
itself	 beginning	 to	 express	ANXA1	during	 tissue	 repair,	 as	 noted	 previously	 (Bizzarro	 et	 al.,	 2012),	
experiments	with	chimeric	mice	confirmed	that	the	most	important	source	of	the	protein	to	enable	
muscle	 repair	 remains	 the	 myeloid	 cells	 themselves.	 While	 the	 current	 studies	 do	 not	 permit	
conclusive	 determination	 of	 whether	 neutrophils	 or	 macrophages	 are	 the	 primary	 source	 of	
endogenous	 ANXA1	 in	 the	 injured	 tissue,	 neutrophils	 contain	 substantial	 quantities	 of	 ANXA1	
(Francis	 et	 al.,	 1992),	which	we	 have	 previously	 shown	 to	 be	 a	major	monocyte	 chemoattractant	
(McArthur	et	al.,	2015)	suggesting	that	the	protein	-	produced	at	an	early	stage	by	and	released	from	
infiltrating	neutrophils	(Damazo	et	al.,	2006)	-	may	act	to	both	recruit	monocytes	and	promote	a	pro-
resolving	 phenotype	 in	 resulting	 macrophages.	 Whatever	 the	 ultimate	 cellular	 source	 of	 ANXA1	
however,	 the	 dependency	 upon	 the	 presence	 of	 ANXA1-expressing	 leukocytes	 for	 efficient	
macrophage	phenotypic	conversion	is	another	example	of	how	“the	beginning	programs	the	end”	in	
resolution	(Serhan	and	Savill,	2005),	emphasising	the	finely	tuned	nature	of	the	acute	inflammatory	
response	and	its	ability	to	encode	its	own	termination.	
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Besides	highlighting	the	role	of	ANXA1	as	a	regulator	of	inflammatory	resolution	(Leoni	and	Nusrat,	
2016),	 these	new	data	add	 further	weight	 to	 the	 importance	of	 its	principal	 receptor	 FPR2/ALX	 in	
this	 process,	 identifying	 it	 as	 a	 conduit	 for	 induction	 of	 a	 pro-resolving	 macrophage	 phenotype	
through	AMPK	 activation.	 It	 is	 notable	 that	macrophage	 FPR2/ALX	 expression	 declined	 during	 the	
course	 of	 the	 response	 to	 muscular	 injury	 in	 our	 study;	 similarly,	 FPR2/ALX	 expression	 was	
significantly	lower	on	M2	when	compared	with	M1	phenotype	cells	in	vitro.	This	change	in	receptor	
expression	may	reflect	a	strategy	whereby	once	the	macrophage	 is	polarised	towards	a	 reparative	
phenotype,	the	utility	of	the	FPR2/ALX	signalling	is	then	limited	or	unnecessary.	
	
There	is	considerable	redundancy	in	the	mediators	known	to	induce	the	conversion	of	macrophage	
phenotypes,	as	is	perhaps	to	be	expected	given	the	importance	of	this	process	to	the	restoration	of	
homeostasis	after	infection	or	damage,	including	immune	complexes,	apoptotic	cells	and	a	number	
of	 cytokines	 (Amici	 et	 al.,	 2017).	 Notably	 however,	 a	 significant	 proportion	 of	 the	 soluble	 pro-
resolving	 mediators	 so	 far	 identified	 derive	 from	 the	 adaptive	 arm	 of	 the	 immune	 response,	
particularly	 from	 TH2	 lymphocytes	 (Martinez	 and	 Gordon,	 2014).	 Our	 data	 however,	 highlight	 the	
ability	 of	 signalling	 components	 derived	 from	 the	 innate	 side	 of	 the	 immune	 system	 to	 promote	
resolution	in	the	absence	of	significant	activation	of	adaptive	mechanisms.	Moreover,	these	results	
support	 the	 concept	of	how	 it	 is	 crucial	 to	decipher	which	mediator	and	 signal(s)	 are	operative	 in	
specific	tissues	and	organs	to	control	macrophage	polarization	and	the	overall	process	of	resolution	
and	repair.		
	
Our	 data	 are	 the	 first	 to	 associate	 activation	 of	 FPR2/ALX	 and	 the	 major	 regulator	 of	 cellular	
metabolism,	AMPK,	showing	the	central	involvement	of	FPR2/ALX-stimulated	AMPK	activation	in	the	
induction	of	a	pro-resolving	macrophage	phenotype.	The	precise	mechanism	linking	AMPK	activation	
with	a	change	 in	phenotype	 is	as	yet	unclear,	but	 there	 is	 increasing	evidence	 that	changes	 in	 the	
metabolic	status	of	 immune	cells	can	affect	their	 inflammatory	activity	(O'Neill	et	al.,	2016;	Pearce	
and	 Pearce,	 2013).	 Pro-inflammatory	 dendritic	 cells	 and	 T	 lymphocytes	 are	 characterised	 by	 high	
levels	 of	 glycolysis,	 akin	 to	 the	Warburg	 shift	 described	 in	 cancer	 (Rodriguez-Prados	 et	 al.,	 2010),	
whereas	 immune	 cells	 with	 an	 anti-inflammatory	 or	 pro-resolving	 profile	 tend	 to	 exhibit	 greater	
mitochondrial	 respiration	 (Jha	 et	 al.,	 2015;	 Mounier	 et	 al.,	 2013;	 Tannahill	 et	 al.,	 2013).	 The	
mechanistic	 details	 of	 how	 such	 changes	 in	metabolic	 phenotype	 relate	 to	 immune	 function,	 and	
indeed	whether	these	differences	reflect	or	drive	immunophenotype	is	unclear	(Van	den	Bossche	et	
al.,	2017),	but	 it	 is	notable	 that	AMPK	 is	a	 significant	promoter	of	mitochondrial	 respiration	and	a	
regulator	 of	 glycolysis	 through	 the	 modulation	 of	 lactate	 dehydrogenase	 activity	 (Theret	 et	 al.,	
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2017),	driven	by	its	ability	to	respond	to	energy	debt	and	an	increased	AMP:ATP	ratio	(Mounier	et	
al.,	2015).	Activation	of	this	pathway	would	therefore	seem	ideally	placed	to	 induce	the	metabolic	
phenotype	 most	 closely	 associated	 with	 anti-inflammatory	 macrophage	 activation,	 but	 this	
hypothesis	requires	further	investigation.	
	
AMPK	 is	 involved	 in	 different	 cellular	 mechanisms	 that	 regulate	 skeletal	 muscle	 homeostasis	
(Kjobsted	et	al.,	2018).	Our	previous	 findings	highlight	 the	 importance	of	crosstalk	between	AMPK	
and	 the	 mTOR	 signaling	 pathway	 for	 the	 control	 of	 muscle	 cell	 size	 in	 the	 adaptive	 response	 of	
skeletal	muscle	(Lantier	et	al.,	2014;	Lantier	et	al.,	2010;	Mounier	et	al.,	2011;	Mounier	et	al.,	2009).	
Moreover,	 we	 have	 recently	 shown	 that	 AMPKα1,	 activated	 following	 phagocytosis,	 is	 crucial	 for	
macrophage	skewing	from	a	pro-	to	an	anti-inflammatory	phenotype	during	resolution	(Mounier	et	
al.,	 2013),	 demonstrating	 that	 the	 CAMKKII/AMPKα1	 pathway	within	macrophages	 is	 required	 for	
proper	 and	 complete	 skeletal	 muscle	 regeneration.	 Anti-inflammatory	 macrophages	 promote	
myogenic	differentiation	and	fusion	(Saclier	et	al.,	2013a;	Saclier	et	al.,	2013b;	Varga	et	al.,	2016b),	a	
finding	of	importance	for	skeletal	muscle	muscle	regeneration	where	a	sequential	presence	of	pro-	
then	 anti-inflammatory	 cells	 is	 necessary	 for	 efficient	 regeneration	 process	 (Arnold	 et	 al.,	 2007;	
Varga	et	al.,	2013).	Therefore,	the	pro-resolving	effect	of	ANXA1-AMPK	signalling	in	macrophages	is	
likely	 to	 be	 beneficial	 for	 skeletal	 muscle	 regeneration,	 as	 suggested	 by	 the	 positive	 effect	 of	
conditioned	medium	from	ANXA1-treated	macrophages	on	adult	myogenesis	in	vitro.	
	
In	 summary,	 we	 present	 here	 a	 novel	 mechanism	 governing	 the	 conversion	 of	 pro-inflammatory	
macrophages	 to	 a	 pro-resolving	 phenotype,	 linking	 leukocyte-derived	 ANXA1,	 FPR2/ALX	 and	
intracellular	AMPK	activation.	This	 finding	reinforces	the	position	of	the	ANXA1-FPR2/ALX	pathway	
as	 a	 pivotal	 regulator	 of	 inflammatory	 resolution,	 and	 suggests	 that	 it	 may	 represent	 a	 suitable	
target	 for	 therapeutic	 exploitation	 for	 the	 innovative	 treatment	 of	 pathologies	 characterised	 by	
chronic,	non-resolving	inflammation.		
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Figure	Legends	
Figure	1.	Non-redundant	role	of	ANXA1	in	cardiotoxin-induced	muscle	injury	and	repair.	
(A)	 Experimental	 set-up.	 Acute	 injury	 was	 induced	 by	 cardiotoxin	 (CTX)	 injection	 in	 the	 Tibialis	
Anterior	(TA)	of	Wild-Type,	AnxA1-/-	and	Fpr2/3-/-	mice.	Muscles	were	analysed	0,	7	and	28	days	after	
injury.	(B)	TA	mass	normalised	to	mouse	body	weight.	(C)	Hematoxylin-eosin	(HE)	staining	of	muscles	
28	days	after	 injury.	White	bar	=	50	μm.	 (D-E)	Myofiber	cross-sectional	area	 (D),	number	of	nuclei	
per	myofiber	 (E)	 and	 lipid	accumulation	 (F)	 in	muscles	28	days	post-CTX	 injury.	 (G-H)	Macrophage	
subtypes	analysis	2	days	post-CTX	 injury.	Shown	are	the	percentage	of	pro-	and	anti-inflammatory	
macrophages	within	the	F4/80+	population	(G)	and	the	resolution	index	(H).	Results	are	mean	±	SEM	
of	at	least	three	animals.	*p<0.05,	**p<0.01	and	***p<0.001	versus	Wild-Type.	
	
Figure	2.	Infiltrating	myeloid	cell-derived	ANXA1	controls	muscle	repair.		
(A)	Experimental	set-up.	CX3CR1-GFP	mice	were	irradiated	and	then	transplanted	with	bone	marrow	
cells	 isolated	from	Wild-Type	or	AnxA1-/-	mice.	Bone	marrow	engraftment	was	checked	on	a	blood	
sample	 after	 around	 5	 weeks.	 Then	 animals	 were	 injured	 in	 their	 Tibialis	 Anterior	 by	 cardiotoxin	
(CTX)	 injection	 and	muscles	 analysed	 0	 or	 28	days	 later.	 Engraftment	was	 confirmed	on	 the	bone	
marrow	of	each	animal	on	the	day	of	sacrifice.	(B-C)	Representative	FACS	plots	(B)	and	quantification	
(C)	of	 the	GFP+	monocytes	 in	 the	bone	marrow	of	 the	sacrificed	animals.	 (D-E)	HE	staining	 (D)	and	
myofiber	cross-sectional	area	(E)	of	TA	muscles	28	days	post-CTX	injury.	White	bar	=	50	μm.	Results	
are	mean	±	SEM	of	at	least	four	muscles.	*p<0.05	versus	Wild-Type.	
	
Figure	3.	Exogenous	hrANXA1	controls	human	and	mouse	macrophage	polarization	in	vitro.	
Human	PBMC-derived	macrophages	were	incubated	for	24	hours	with	LPS+IFNγ	to	promote	an	M1-
like	 phenotype,	 prior	 to	 addition	 of	 human	 recombinant	 ANXA1	 (hrANXA1,	 10nM)	 for	 further	 6	
hours.	 (A-B)	 Mean	 Fluorescent	 Intensity	 (MFI)	 units	 measured	 by	 flow	 cytometry	 of	 MHCII	 pro-
inflammatory	 (A)	 and	 CD206	 anti-inflammatory	 (B)	 markers.	 Shown	 are	 MFI	 quantification	 (left	
panel)	and	representative	FACS	plots	(right	panel).	(C-F)	RT-qPCR	analysis	of	Tnfa	(C)	and	Nos-2	(D)	
pro-inflammatory	 genes,	 and	 Il-10	 (E)	 and	 Tgfb1	 (F)	 anti-inflammatory	 genes.	 (G-H)	 MFI	 units	 as	
measured	 by	 flow	 cytometry	 of	 MHCII	 pro-inflammatory	 (G)	 and	 CD206	 anti-inflammatory	 (H)	
markers	after	treatment	by	hrANXA1	in	the	presence	or	absence	of	the	FPR2/ALX	antagonist	WRW4	
(10	µM).	Results	are	mean	±	SEM	of	at	least	three	independent	experiments.	*p<0.05	versus	Vehicle.	
#p<0.05	versus	Control.	
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Figure	 4.	 The	 ANXA1/FPR2/ALX	 pathway	 activates	 the	 AMPK	 signalling	 cascade	 in	 human	 and	
murine	macrophages.	
(A)	Schematic	representation	of	the	ANXA1/FPR2/ALX	signalling	cascade.	(B-D)	Western	blot	analysis	
of	pCaMK,	pAMPKα1	and	pACC	in	human	PBMC-derived	macrophages	treated	with	hrANXA1.	Shown	
are	 representative	 blots	 (B)	 and	 quantification	 of	 pAMPKα1	 to	 AMPKα1	 (C)	 and	 pACC	 to	 ACC	 (D)	
ratios.	(E)	Representative	western	blot	(top	panel)	and	quantification	(bottom	panel)	of	pAMPKα1	to	
AMPKα1	 ratio	 in	 human	 PBMC-derived	 macrophages	 treated	 by	 hrANXA1	 in	 the	 presence	 or	
absence	 of	 10	µM	WRW4.	 (F)	 Representative	western	 blot	 (top	 panel)	 and	 quantification	 (bottom	
panel)	 of	 pAMPKα1	 to	 AMPKα1	 ratio	 in	 Wild-Type	 or	 Fpr2/3-/-	 murine	 bone	 marrow	 derived	
macrophages	 treated	 with	 hrANXA1.	 Results	 are	 means	 ±	 SEM	 of	 at	 least	 three	 independent	
experiments.	*p<0.05,	**p<0.01	versus	Vehicle.	
	
Figure	5.	Null	or	reduced	AMPK	expression	affects	ANXA1-mediated	macrophage	polarization.	
(A-B)	 Primary	 macrophages	 derived	 from	Wild-Type	 or	 AMPKα1-/-	 mice	 were	 treated	 with	 10nM	
hrANXA1	and	 the	percentage	of	 cells	expressing	 the	pro-inflammatory	markers	 iNOS	and	CCL3	 (A)	
and	 the	 anti-inflammatory	 markers	 TGFB1,	 CD163	 and	 CD206	 (B)	 was	 determined	 by	
immunofluorescence.	(C-E)	Human	PBMC-derived	macrophages	were	transfected	by	a	non-targeting	
or	 three	 different	 AMPKα1-targeting	 siRNAs	 and	 treated	with	 10	 nM	 hrANXA1	 for	 24	 h.	 AMPKα1	
protein	level	was	determined	by	western	blot	(C)	and	the	MFI	units	of	the	pro-inflammatory	MHCII	
(D)	and	anti-inflammatory	CD206	 (E)	markers	were	measured	by	 flow	cytometry.	 (F-I)	Conditioned	
medium	 produced	 by	 murine	 macrophages	 was	 transferred	 onto	 murine	 primary	 myoblasts	 and	
their	 fusion	 was	 measured	 by	 immunofluorescence.	 (F)	 Experimental	 set-up.	 (G)	 Representative	
images	of	desmin	(red)	and	Hoechst	(blue)	 labelling	of	myoblast	cultures.	White	bar	=	50	μm.	(H-I)	
Fusion	 index	 calculated	 after	 desmin	 labelling.	 Shown	are	 the	means	 +/-	 SEM	of	 the	 independent	
experiments	(H)	and	the	results	of	each	 individual	replicate	(I).	Results	are	mean	±	SEM	of	at	 least	
three	independent	experiments.	*p<0.05	versus	Mock	or	Control.	##p<0.01	versus	Wild-Type.	
	
Suppl	 Fig	 1.	 Related	 to	 Figure	 1.	 Immune	 cell	 recruitment	 and	 pattern	 of	 AnxA1	 expression	 in	
cardiotoxin-induced	muscle	injury	and	repair.	
Immunofluorescence	analysis	of	ANXA1	protein	 in	Tibialis	Anterior	muscle	after	 cardiotoxin	 injury.	
Images	 show	co-localisation	of	ANXA1	protein	with	 Ly6G+	 (A)	 and	F4/80+	 (B)	 cells.	White	bar	=	50	
μm.	(C)	Quantification	of	F4/80+	ANXA1+	cells	in	Tibialis	Anterior	(TA)	muscle	after	cardiotoxin	(CTX)	
injury.		
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Suppl	 Fig	 2.	Related	 to	 Figure	1.	 Immune	 cell	 recruitment	 and	 Fpr2/3	expression	 in	 cardiotoxin-
induced	muscle	injury	and	repair.	
Quantification	of	F4/80+	ANXA1+	cells	 in	Tibialis	Anterior	 (TA)	muscle	after	 cardiotoxin	 (CTX)	 injury	
(A),	 representative	 immunofluorescence	 analysis	 of	 Fpr2/3	 protein	 in	 TA	muscle	 after	 cardiotoxin	
(CTX)	injury	(B)	and	quantification	of	the	percentage	of	F4/80+	cells	expressing	Fpr2/3	(C).	White	bar	
=	50	μm.		Results	are	means	±	SEM	of	three	animals.	*p<0.05	and	***p<0.001	versus	Day	0.		
	
Suppl	Fig	3.	Related	to	Figure	1	and	2.			
(A)	HE	staining	of	non-injured	Wild-Type	and	AnxA1-/-	Tibialis	Anterior	(TA)	muscles.	White	bar	=	50	
μm.	 (B)	 Representative	 FACS	plots	 of	 F4/80	 and	 Ly6C/G	markers	 in	 TA	of	Wild-Type,	 AnxA1-/-	 and	
Fpr2/3-/-	mice	2	days	post-cardiotoxin	injury.	(C)	Weight	follow-up,	represented	as	percentage	of	Day	
0,	of	mice	after	irradiation	and	bone	marrow	transplantation.	Results	are	means	±	SEM	of	at	least	six	
animals.	*p<0.05	versus	Day	0	
	
Suppl	 Fig	 4.	 Related	 to	 Figure	 3.	 FPR2/ALX	 expression	 varies	 following	 human	 macrophage	
polarization.	
Human	 primary	 macrophages	 were	 polarised	 into	 M1	 or	 M2	 macrophages	 with	 IFNg	 and	 IL-4,	
respectively	(A-C)	Flow	cytometry	analysis	of	FPR2/ALX	expression.	Shown	are	representative	FACS	
plots	(A),	percentage	of	cells	expressing	FPR2/ALX	(B)	and	FPR2/ALX	MFI	(C).	(D)	RT-qPCR	analysis	of	
FPR2/ALX	mRNA	 level.	Results	 are	means	+/-	 SEM	of	 at	 least	 four	 independent	experiments.	 *p	<	
0.05	versus	M0	(non-activated).	
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Methods	
Animals		
All	procedures	were	performed	under	the	UK	Animals	(Scientific	Procedures)	Act,	1986	in	the	UK	or	
in	 compliance	 with	 European	 legislation	 in	 France.	 Animal	 facilities	 are	 fully	 licensed	 by	 relevant	
national	 authorities	 and	 protocols	 have	 been	 validated	 by	 ethical	 committee.	Male	 C57Bl/6	mice,	
male	alx/fpr2/3GFP/GFP	mice	(referred	to	as	Fpr2/3-/-)	bearing	a	knocked-in	green	fluorescent	protein	
(Dufton	et	al.,	2010)	and	male	anxA1-/-	mice	(Hannon	et	al.,	2003),	aged	10	weeks	were	used	for	 in	
vivo	experiments.	Both	transgenic	strains	were	fully	backcrossed	onto	a	C57Bl/6	genetic	background.		
	
Production	of	Recombinant	Human	Annexin	A1	
Human	recombinant	annexin	A1	 (hrANXA1)	was	produced	by	a	prokaryotic	expression	system	and	
purified	essentially	as	described	previously	(Kusters	et	al,	2015).	Briefly,	cDNA	for	human	ANXA1	was	
inserted	into	the	expression	vector	pQE30Xa	(Qiagen)	and	transfected	into	E.coli	(#SG13009	pREP4,	
Novagen)	which	were	then	grown	in	Luria-Bertani	broth	medium	supplemented	with	ampicillin	(50	
μg/ml,	Roche),	kanamycin	(30	μg/ml,	Thermofisher)	and	0.5%	glycerol.	Protein	overexpression	was	
initiated	by	addition	of	5mM	isopropyl	β-D-1-thiogalactopyranoside	(Eurogentec)	and	proteins	were	
purified	by	IMAC.	Purity	and	homogeneity	were	assessed	by	SDS-PAGE,	western	blotting	and	MALDI-
TOF/TOF	 analysis.	 Endotoxin	 was	 determined	 with	 the	 Endosafe-PTS	 (FDA-licensed	 LAL	 cartridge	
from	 Charles-River)	 according	 to	 the	 manufacturer’s	 protocol.	 HrANXA1	 contained	 <	 0.2	 unit	
endotoxin	per	mg	hrANXA1	protein.	
	
Skeletal	Muscle	Injury	
Skeletal	muscle	injury	was	caused	by	intramuscular	 injection	of	cardiotoxin	(Latoxan)	 in	the	Tibialis	
Anterior	(TA)	muscle	of	male	animals,	as	described	previously	(Mounier	et	al.,	2013).	Left	TA	muscles	
were	 injected	with	cardiotoxin	 (50	µl	per	TA,	12	µM);	1,	2,	7,	14	or	28	days	post-lesioning	animals	
were	 killed	 by	 exposure	 to	 CO2.	 TA	 were	 isolated	 and	 snap-frozen	 in	 liquid	 nitrogen-cooled	
isopentane	for	storage	and	later	analysis.		
	
Murine	Bone	Marrow-Derived	Macrophages		
Bone	 marrow-derived	 macrophages	 (BMDMs)	 were	 prepared	 from	 adult	 male	 wild-type	
sv129/C57Bl6	and	Prkaa1-/-	mice	(referred	to	as	AMPKα1-/-	(Jorgensen	et	al.,	2005)).	Mice	were	killed	
by	 cervical	 dislocation	 under	 isofluorane	 anaesthesia,	 and	 marrow	 was	 flushed	 from	 tibiae	 and	
femurs.	 Cells	were	plated,	washed	and	 grown	 for	 6-7	days	 in	DMEM	High	Glucose	High	Pyruvate,	
20%	 heat	 inactivated	 fetal	 calf	 serum	 (ThermoFisher),	 30%	 L929-cell	 conditioned	 medium,	 1%	
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Amphotericin	 B	 (2.5	 µg/ml,	 ThermoFisher)	 and	 100	 μg/ml	 streptomycin	 (ThermoFisher).	 For	
phenotypic	characterisation,	BMDMs	were	fixed	for	10	minutes	in	4%	formaldehyde,	permeabilized	
for	10	minutes	in	PBS	with	0.5	%	Triton	X-100	and	blocked	for	1	hour	in	PBS	with	4	%	BSA.	They	were	
then	 labeled	 overnight	 at	 4°C	 with	 anti-NOS2	 (#ab15323,	 Abcam),	 anti-CCL3	 (#ab32609,	 Abcam),	
anti-TGFβ1	 (#ab64715,	 Abcam),	 anti-CD163	 (#sc-20066,	 Santa-Cruz)	 and	 anti-CD206	 (#sc-58987,	
Santa-Cruz),	 followed	 by	 incubation	 for	 1	 hour	 at	 37°C	 with	 FITC-	 or	 Cy3-conjugated	 secondary	
antibodies	(Jackson	Immunoresearch	Inc).	Cells	were	stained	with	Hoechst	(Sigma)	and	mounted	in	
Fluoromount	 (Interchim)	 and	 pictures	 were	 taken	 on	 an	 Axio	 Imager.Z1	 (Zeiss)	 at	 20X	 of	
magnification	connected	to	a	CoolSNAP	MYO	CCD	Camera	(Photometrics).	
	
In	vitro	model	of	adult	myogenesis	
Macrophages	were	obtained	from	bone	marrow	(BM)	precursor	cells	 that	were	cultured	 in	DMEM	
containing	20%	FBS	and	30%	conditioned	medium	of	 L929	 cell	 line	 (enriched	 in	CSF-1)	 for	7	days.	
Macrophages	 were	 activated	 with	 human	 recombinant	 annexin	 A1	 for	 3	 days	 (10	 nM)	 in	 DMEM	
containing	 10%	 FBS.	 After	 the	 washing	 steps,	 serum-free	 DMEM	 was	 added	 for	 24	 hr	 to	 obtain	
macrophage-conditioned	medium.	Murine	myogenic	precursor	cells	(MPCs)	were	obtained	from	TA	
muscle	 and	 cultured	 using	 standard	 conditions	 in	 DMEM/F12	 medium	 (Gibco	 Life	 Technologies)	
containing	20%	heat	inactivated	Foetal	Bovine	Serum	(FBS)	and	2%	G/Ultroser	(Pall	Inc).	MPCs	were	
seeded	 at	 30,000	 cell/cm2	 on	 Matrigel	 (diluted	 1:10)	 and	 incubated	 for	 3	 days	 with	 conditioned	
medium	containing	2%	heat	inactivated	horse	serum.	Cells	were	then	incubated	with	an	anti-desmin	
antibody	 (#ab32362,	 Abcam),	 followed	 by	 a	 Cy3-conjugated	 secondary	 antibody	 (Jackson	
Immunoresearch	 Inc)	 (Mounier	 et	 al,	 2013;	 Varga	 et	 al,	 2016).	 Cells	 were	 stained	 with	 Hoechst	
(Sigma)	 and	 mounted	 in	 Fluoromount	 (Interchim)	 and	 pictures	 were	 taken	 on	 Axio	 Observer.Z1	
(Zeiss)	at	20X	of	magnification	connected	to	a	CoolSNAP	HQ2	CCD	Camera	(Photometrics	
	
Bone	Marrow	Transplantation	
Total	bone	marrow	cells	were	isolated	by	flushing	the	tibiae	and	femurs	of	8-	to	20-week-old	donor	
mice	(wild-type	or	AnxA1-/-	males)	with	RPMI-1640	/	10%	FBS.	They	were	transplanted	into	8-	to	12-
week-old	 recipient	 CX3CR1-GFP+/-	 males	 (monocytes/macrophages	 expressing	 GFP)	 previously	
lethally	 irradiated	 for	10	min	with	a	dose	of	0.85	Gy/min	 in	an	X-RAD	320	 (Precision	X-Ray).	 Total	
bone	marrow	cells	were	injected	(107	cells	diluted	in	100	μL	of	RPMI-1640	/	50	%	mouse	serum)	into	
the	retro-orbital	vein	of	recipient	mice.	After	transplantation,	mice	were	fed	with	ciprofloxacin	(10	
mg/kg/day)	in	the	drinking	water	for	3-weeks.	Engraftment	efficiency	was	determined	on	peripheral	
blood	5	weeks	after	 the	 transplantation	and	on	bone	marrow	when	mice	were	 sacrificed	by	FACS	
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analysis.	 Briefly,	 red	 cells	 were	 lysed	 with	 ACK	 buffer	 and	 leukocytes	 were	 incubated	 with	 FcR	
Blocking	 Reagent	 (Miltenyi	 Biotec)	 for	 20	 min	 at	 4°C.	 Finally,	 cells	 were	 labeled	 with	 an	 APC-
conjugated	 anti-CD115	 antibody	 for	 30	 min	 at	 4°C	 and	 analysed	 on	 a	 BD	 FACS	 Canto	 II	 (BD	
Biosciences).	DAPI	was	used	as	viability	marker.	Engraftment	was	determined	as	the	percentage	of	
monocytes	not	expressing	GFP.	
	
Human	Peripheral	Blood-Derived	Macrophages	
Human	 cells	 were	 prepared	 according	 to	 an	 approved	 protocol	 (East	 London	 &	 the	 City	 Local	
Research	 Ethics	 Committee;	 no.	 06/Q605/40;	 P/00/029).	 Peripheral	 blood	 was	 collected	 from	
healthy	 volunteers	 by	 intravenous	 withdrawal	 in	 3.2%	 sodium	 citrate	 solution	 (1:10).	 Peripheral	
blood	 mononuclear	 cells	 were	 isolated	 by	 density	 centrifugation	 on	 a	 Histopaque-1077	 gradient	
(Sigma)	according	to	the	manufacturer’s	instructions,	and	were	plated	in	RPMI	1640	for	1	hour.	Cells	
were	washed	three	times	with	ice-cold	PBS	without	Ca2+/Mg2+	to	remove	lymphocytes,	and	adherent	
cells	were	incubated	in	RPMI	1640	containing	20%	heat	inactivated	fetal	calf	serum	for	14	days.	
	
Histological	and	Immunohistochemical	Analysis	
For	histological	analysis,	muscles	were	harvested,	snap	 frozen	 in	 liquid	nitrogen-chilled	 isopentane	
and	kept	at	-80°C	until	use.	Cryosections	(10µm)	were	prepared	for	hematoxylin-eosin	(HE)	or	Sudan	
Black	 staining.	 Fluorescence	 immunohistochemical	 analysis	 was	 performed	 according	 to	 standard	
procedures.	 Briefly,	 transverse	muscle	 cryosections	 (10	 µm)	were	 post-fixed	 by	 incubation	 for	 15	
minutes	in	4%	formaldehyde,	blocked	and	immunostained	using	primary	antibodies	directed	against	
Ly6G	 (1:100;	 #127602,	 Biolegend),	 F4/80	 (1:200,	 #123102,	 Biolegend)	 ANXA1	 (1:1,000;	 #71-3400,	
ThermoFisher)	 or	 Fpr2/3	 (1:100,	 #sc-18191-R,	 SantaCruz).	 Secondary	 antibodies	 were	 Alexa	 Fluor	
488-	 or	 594-conjugated	 goat	 anti-rabbit	 or	 anti-rat	 IgG	 (1:300;	 Invitrogen).	 Sections	 were	
counterstained	 with	 DAPI,	 mounted	 and	 examined	 using	 a	 TCS	 SP5	 confocal	 laser	 scanning	
microscope	(Leica	Microsystems)	fitted	with	405	nm,	488	nm	and	594	nm	lasers,	and	attached	to	a	
Leica	 DMI6000CS	 inverted	 microscope	 fitted	 with	 a	 40×	 objective	 lens	 (NA	 0.75	 mm;	 working	
distance,	 0.66	 mm).	 Images	 were	 captured	 with	 Leica	 LAS	 AF	 2.6.1	 software	 and	 analysed	 using	
ImageJ	1.51w	software	(National	Institutes	of	Health).	
	
In	vivo	Macrophage	Phenotype	Analysis	
Macrophage	phenotype	was	analyzed	as	previously	described	(Mounier	et	al.,	2013).	Briefly,	CD45+	
cells	 were	 isolated	 from	 regenerating	 muscle	 TA	 using	 magnetic	 beads	 conjugated	 to	 anti-CD45	
antibody	 (Milteny	 Biotec)	 and	 then	 incubated	 with	 Fc-block	 (Milteny	 Biotec)	 for	 30	 min	 at	 4°C.	
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Finally,	 CD45+	 cells	 were	 stained	 with	 antibody	 against	 Ly-6C/G	 (#17-5931-82,	 eBioscience)	 and	
against	 F4/80	 (#12-4801-82,	 eBioscience).	 Percentages	 of	 Ly-6C/GhiF4/80low	 and	 Ly-6C/GnegF4/80hi	
cells	 were	 calculated	 among	 total	 F4/80pos	 cells	 following	 analysis	 by	 flow	 cytometry	 with	 a	
FACSCalibur	 instrument	 (Becton	 Dickinson,	 UK)	 and	 FlowJo	 v.9.2	 analysis	 software	 as	 described	
below.	
	
AMPKα1	siRNA	
Primary	 human	 PBMC-derived	 macrophages	 were	 transfected	 with	 one	 of	 three	 different	
commercial	 siRNA	 sequences	 designed	 to	 target	 AMPKα1	 or	 an	 Allstars	 negative	 control	 siRNA	
sequence	 using	 Hiperfect	 transfection	 reagent	 according	 to	 the	manufacturer’s	 instructions	 (final	
concentration	2	nM;	all	Qiagen	GmbH,	Hilden,	Germany),	alongside	mock	transfected	cells.	After	48	
hours,	 cells	 were	 analysed	 for	 phenotypic	 conversion	 following	 hrANXA1	 treatment	 (6	 hours,	 10	
nM).	 A	 proportion	 of	 cells	 were	 analysed	 for	 AMPKα1	 expression	 by	 western	 blot	 using	 a	 rabbit	
polyclonal	 antibody	 raised	 against	 human	 the	 AMPKα1	 subunit	 (1:1,000,	 #2795,	 Cell	 Signalling	
Technology)	 and	 for	 β-actin	 expression	 using	 a	 mouse	 monoclonal	 antibody	 (1:10,000;	 #A5316,	
Sigma).		
	
Human	Macrophage	Flow	Cytometry	Analysis	
Primary	human	PBMC-derived	macrophages	were	labelled	with	FITC-conjugated	mouse	monoclonal	
anti-MHCII	 (#11-9956-42,	 Thermofisher)	 and	 APC-conjugated	mouse	monoclonal	 anti-CD206	 (#17-
2069-42,	Thermofisher)	or	isotype	controls	(all	Thermofisher)	according	to	manufacturer’s	protocols.	
In	 all	 cases,	 20,000	 events	were	 acquired	 using	 a	 FACSCalibur	 flow	 cytometer	 (Becton	Dickinson),	
and	analysed	using	FlowJo	analysis	software	(Version	9.2,	Treestar	Inc).	In	some	cases,	macrophages	
were	analysed	for	surface	expression	of	FPR2/ALX;	surface	FcγR	were	blocked	by	incubation	for	20	
minutes	at	4°C	with	IgG	block	(ThermoFisher	Scientific,	UK),	followed	by	incubation	for	30	minutes	at	
4°C	with	mouse	monoclonal	 anti-FPR2/ALX	 (1µg/106	 cells;	 GM1D6,	 Aldevron,	 Freiburg,	 Germany)	
then	incubation	for	30	minutes	at	4°C	with	secondary	antibody	(AF488-conjugated	goat	anti-mouse	
1:300;	ThermoFisher	Scientific,	UK).		
	
Western	Blot	Analysis	
Samples	 boiled	 in	 6×	 Laemmli	 buffer	 were	 subjected	 to	 standard	 SDS-PAGE	 (10%)	 and	
electrophoretically	 blotted	 onto	 Immobilon-P	 polyvinylidene	 difluoride	 membranes	 (Millipore,	
Watford,	 UK).	 Membranes	 were	 incubated	 with	 antibodies	 raised	 against	 human	 phospho-
Ca2+/calmodulin-dependent	 kinase	 (#12716,	 Cell	 Signalling	 Technology),	 phospho-AMPKα1	 (#2531,	
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Cell	 Signalling	 Technology),	 AMPKα1	 (#2795,	 Cell	 Signalling	 Technology),	 phospho-acetyl-CoA	
carboxylase	 (#3661,	 Cell	 Signalling	 Technology),	 acetyl-CoA	 carboxylase	 (#3662,	 Cell	 Signalling	
Technology,	all	1:1000)	or	β-actin	(1:10,000;	#A5316,	Sigma)	in	Tris-buffer	saline	solution	containing	
0.1	%	Tween-20	and	5	%	(w/v)	non-fat	dry	milk	overnight	at	4	°C.	Membranes	were	washed	for	30	
minutes	with	Tris-buffer	saline	solution	containing	0.1	%	Tween-20,	with	the	solution	being	changed	
at	 10	 minute	 intervals;	 membranes	 were	 then	 incubated	 with	 secondary	 antibody	 (horseradish	
peroxidase–conjugated	goat	anti-mouse	1:5000;	ThermoFisher),	 for	2	hours	at	 room	 temperature.	
Proteins	were	then	detected	using	the	enhanced	chemiluminescence	detection	kit	and	visualized	on	
Hyperfilm	(Amersham	Biosciences).	Films	were	digitised	and	analysed	using	ImageJ	1.51w	software	
(National	Institutes	of	Health).	
	
Quantitative	RT-PCR	
Total	RNA	was	prepared	from	primary	human	PBMC-derived	macrophages	using	TRIzol	reagent	(Life	
Technologies	 Ltd),	 and	 then	 reverse	 transcribed	 with	 superscript	 III	 reverse	 transcriptase	 (Life	
Technologies	Ltd)	according	to	the	manufacturer’s	protocols.	Resultant	cDNA	was	then	analysed	by	
real-time	PCR	in	duplicate,	using	the	Quantitect	primer	system	(Primer	sets:	FPR2/ALX	QT00204295,	
IL-10	QT00041685,	NOS-2	QT00068740,	TNF-α	QT00029162	and	TGFβ1	QT00000728;	all	Qiagen	Ltd.)	
and	Power	SYBR	Green	PCR	Master	Mix	(Applied	Biosystems).	Reactions	were	performed	in	384	well-
format	using	the	ABI	Prism	7900HT	Sequence	Detection	System.	The	PCR	conditions	consisted	of	95	
°C	15	min,	[95	°C	15	s − 55	°C	30	s − 72	°C	30	s] × 40,	with	a	dissociation	step	[95	°C	15	s/60	°C	15	s/95	
°C	15	s]	 included	after	the	PCR	reaction	to	confirm	the	absence	of	non-specific	products.	Data	was	
acquired	and	analyzed	with	SDS	2.3	(Applied	Biosystems);	fold	change	was	calculated	as	2−ΔΔCt.	
	
Statistical	Analysis	
All	 quantified	 in	 vitro	 data	 are	derived	 from	at	 least	 three	 independent	 donors,	with	 experiments	
performed	 in	 triplicate,	 and	 are	 expressed	 as	 mean	 ±	 SEM.	 Murine	 in	 vivo	 experiments	 were	
performed	with	a	group	size	of	n=6,	sufficient	to	identify	a	20%	effect	size	with	a	power	of	0.8,	and	
are	expressed	as	mean	±	SEM.	Data	were	analyzed	by	one-	or	two-way	ANOVA	as	appropriate,	with	
post	hoc	comparison	using	Tukey’s	HSD	test.	For	murine	in	vitro	experiments,	at	least	3	independent	
experiments	were	performed	and	statistical	significance	was	determined	using	Student’s	t	test.	In	all	
cases,	a	P<0.05	was	taken	as	indicating	statistical	significance.	
	 	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 22	
References		
	
Amici,	 S.A.,	 Dong,	 J.,	 and	 Guerau-de-Arellano,	 M.	 (2017).	 Molecular	 Mechanisms	Modulating	 the	
Phenotype	of	Macrophages	and	Microglia.	Front	Immunol	8,	1520.	
Arnold,	 L.,	 Henry,	 A.,	 Poron,	 F.,	 Baba-Amer,	 Y.,	 van	 Rooijen,	 N.,	 Plonquet,	 A.,	 Gherardi,	 R.K.,	 and	
Chazaud,	 B.	 (2007).	 Inflammatory	 monocytes	 recruited	 after	 skeletal	 muscle	 injury	 switch	 into	
antiinflammatory	macrophages	 to	support	myogenesis.	The	 Journal	of	experimental	medicine	204,	
1057-1069.	
Bizzarro,	 V.,	 Belvedere,	 R.,	 Dal	 Piaz,	 F.,	 Parente,	 L.,	 and	 Petrella,	 A.	 (2012).	 Annexin	 A1	 induces	
skeletal	muscle	cell	migration	acting	through	formyl	peptide	receptors.	PLoS	One	7,	e48246.	
Chan,	K.L.,	Pillon,	N.J.,	Sivaloganathan,	D.M.,	Costford,	S.R.,	Liu,	Z.,	Theret,	M.,	Chazaud,	B.,	and	Klip,	
A.	 (2015).	 Palmitoleate	 Reverses	 High	 Fat-induced	 Proinflammatory	 Macrophage	 Polarization	 via	
AMP-activated	Protein	Kinase	(AMPK).	The	Journal	of	biological	chemistry	290,	16979-16988.	
d'Albis,	A.,	Couteaux,	R.,	Janmot,	C.,	Roulet,	A.,	and	Mira,	J.C.	(1988).	Regeneration	after	cardiotoxin	
injury	of	 innervated	 and	denervated	 slow	and	 fast	muscles	of	mammals.	Myosin	 isoform	analysis.	
Eur	J	Biochem	174,	103-110.	
Dalli,	J.,	Jones,	C.P.,	Cavalcanti,	D.M.,	Farsky,	S.H.,	Perretti,	M.,	and	Rankin,	S.M.	(2012).	Annexin	A1	
regulates	neutrophil	clearance	by	macrophages	in	the	mouse	bone	marrow.	FASEB	J	26,	387-396.	
Damazo,	 A.S.,	 Yona,	 S.,	 Flower,	 R.J.,	 Perretti,	 M.,	 and	 Oliani,	 S.M.	 (2006).	 Spatial	 and	 temporal	
profiles	for	anti-inflammatory	gene	expression	in	leukocytes	during	a	resolving	model	of	peritonitis.	J	
Immunol	176,	4410-4418.	
Davies,	L.C.,	and	Taylor,	P.R.	(2015).	Tissue-resident	macrophages:	then	and	now.	Immunology	144,	
541-548.	
Dufton,	N.,	Hannon,	R.,	Brancaleone,	V.,	Dalli,	 J.,	Patel,	H.B.,	Gray,	M.,	D'Acquisto,	F.,	Buckingham,	
J.C.,	 Perretti,	 M.,	 and	 Flower,	 R.J.	 (2010).	 Anti-inflammatory	 role	 of	 the	 murine	 formyl-peptide	
receptor	2:	ligand-specific	effects	on	leukocyte	responses	and	experimental	inflammation.	J	Immunol	
184,	2611-2619.	
Francis,	J.W.,	Balazovich,	K.J.,	Smolen,	J.E.,	Margolis,	D.I.,	and	Boxer,	L.A.	(1992).	Human	neutrophil	
annexin	 I	promotes	granule	aggregation	and	modulates	Ca(2+)-dependent	membrane	fusion.	J	Clin	
Invest	90,	537-544.	
Gobbetti,	 T.,	 Coldewey,	 S.M.,	 Chen,	 J.,	 McArthur,	 S.,	 le	 Faouder,	 P.,	 Cenac,	 N.,	 Flower,	 R.J.,	
Thiemermann,	 C.,	 and	 Perretti,	 M.	 (2014).	 Nonredundant	 protective	 properties	 of	 FPR2/ALX	 in	
polymicrobial	murine	sepsis.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	
of	America	111,	18685-18690.	
Hannon,	R.,	Croxtall,	J.D.,	Getting,	S.J.,	Roviezzo,	F.,	Yona,	S.,	Paul-Clark,	M.J.,	Gavins,	F.N.,	Perretti,	
M.,	 Morris,	 J.F.,	 Buckingham,	 J.C.,	 et	 al.	 (2003).	 Aberrant	 inflammation	 and	 resistance	 to	
glucocorticoids	in	annexin	1-/-	mouse.	FASEB	J	17,	253-255.	
Jha,	A.K.,	Huang,	S.C.,	Sergushichev,	A.,	Lampropoulou,	V.,	Ivanova,	Y.,	Loginicheva,	E.,	Chmielewski,	
K.,	 Stewart,	K.M.,	Ashall,	 J.,	 Everts,	B.,	 et	al.	 (2015).	Network	 integration	of	parallel	metabolic	and	
transcriptional	data	reveals	metabolic	modules	that	regulate	macrophage	polarization.	Immunity	42,	
419-430.	
Jorgensen,	 S.B.,	 Wojtaszewski,	 J.F.,	 Viollet,	 B.,	 Andreelli,	 F.,	 Birk,	 J.B.,	 Hellsten,	 Y.,	 Schjerling,	 P.,	
Vaulont,	 S.,	 Neufer,	 P.D.,	 Richter,	 E.A.,	 et	 al.	 (2005).	 Effects	 of	 alpha-AMPK	 knockout	 on	 exercise-
induced	gene	activation	in	mouse	skeletal	muscle.	FASEB	J	19,	1146-1148.	
Kjobsted,	 R.,	 Hingst,	 J.R.,	 Fentz,	 J.,	 Foretz,	 M.,	 Sanz,	 M.N.,	 Pehmoller,	 C.,	 Shum,	M.,	 Marette,	 A.,	
Mounier,	R.,	Treebak,	J.T.,	et	al.	(2018).	AMPK	in	skeletal	muscle	function	and	metabolism.	FASEB	J	
32,	1741-1777.	
Lantier,	 L.,	 Fentz,	 J.,	 Mounier,	 R.,	 Leclerc,	 J.,	 Treebak,	 J.T.,	 Pehmoller,	 C.,	 Sanz,	 N.,	 Sakakibara,	 I.,	
Saint-Amand,	 E.,	 Rimbaud,	 S.,	 et	 al.	 (2014).	 AMPK	 controls	 exercise	 endurance,	 mitochondrial	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 23	
oxidative	capacity,	and	skeletal	muscle	integrity.	FASEB	journal	:	official	publication	of	the	Federation	
of	American	Societies	for	Experimental	Biology.	
Lantier,	 L.,	 Mounier,	 R.,	 Leclerc,	 J.,	 Pende,	 M.,	 Foretz,	 M.,	 and	 Viollet,	 B.	 (2010).	 Coordinated	
maintenance	 of	 muscle	 cell	 size	 control	 by	 AMP-activated	 protein	 kinase.	 FASEB	 journal	 :	 official	
publication	of	the	Federation	of	American	Societies	for	Experimental	Biology	24,	3555-3561.	
Leoni,	G.,	and	Nusrat,	A.	(2016).	Annexin	A1:	shifting	the	balance	towards	resolution	and	repair.	Biol	
Chem	397,	971-979.	
Lim,	L.H.,	and	Pervaiz,	S.	(2007).	Annexin	1:	the	new	face	of	an	old	molecule.	FASEB	J	21,	968-975.	
Locatelli,	I.,	Sutti,	S.,	Jindal,	A.,	Vacchiano,	M.,	Bozzola,	C.,	Reutelingsperger,	C.,	Kusters,	D.,	Bena,	S.,	
Parola,	M.,	Paternostro,	C.,	et	al.	(2014).	Endogenous	annexin	A1	is	a	novel	protective	determinant	
in	nonalcoholic	steatohepatitis	in	mice.	Hepatology	60,	531-544.	
Lucas,	T.,	Waisman,	A.,	Ranjan,	R.,	Roes,	 J.,	Krieg,	T.,	Muller,	W.,	Roers,	A.,	and	Eming,	S.A.	 (2010).	
Differential	roles	of	macrophages	in	diverse	phases	of	skin	repair.	J	Immunol	184,	3964-3977.	
Maderna,	P.,	Yona,	S.,	Perretti,	M.,	and	Godson,	C.	(2005).	Modulation	of	phagocytosis	of	apoptotic	
neutrophils	by	supernatant	from	dexamethasone-treated	macrophages	and	annexin-derived	peptide	
Ac(2-26).	J	Immunol	174,	3727-3733.	
Mantovani,	A.,	Biswas,	S.K.,	Galdiero,	M.R.,	Sica,	A.,	and	Locati,	M.	(2013).	Macrophage	plasticity	and	
polarization	in	tissue	repair	and	remodelling.	J	Pathol	229,	176-185.	
Martinez,	F.O.,	and	Gordon,	S.	(2014).	The	M1	and	M2	paradigm	of	macrophage	activation:	time	for	
reassessment.	F1000Prime	Rep	6,	13.	
McArthur,	S.,	Gobbetti,	T.,	Kusters,	D.H.,	Reutelingsperger,	C.P.,	Flower,	R.J.,	and	Perretti,	M.	(2015).	
Definition	of	a	Novel	Pathway	Centered	on	Lysophosphatidic	Acid	To	Recruit	Monocytes	during	the	
Resolution	Phase	of	Tissue	Inflammation.	J	Immunol	195,	1139-1151.	
Moraes,	 L.A.,	 Kar,	 S.,	 Foo,	 S.L.,	 Gu,	 T.,	 Toh,	 Y.Q.,	 Ampomah,	 P.B.,	 Sachaphibulkij,	 K.,	 Yap,	 G.,	
Zharkova,	O.,	Lukman,	H.M.,	et	al.	(2017).	Annexin-A1	enhances	breast	cancer	growth	and	migration	
by	 promoting	 alternative	 macrophage	 polarization	 in	 the	 tumour	 microenvironment.	 Sci	 Rep	 7,	
17925.	
Motwani,	 M.P.,	 and	 Gilroy,	 D.W.	 (2015).	 Macrophage	 development	 and	 polarization	 in	 chronic	
inflammation.	Semin	Immunol	27,	257-266.	
Mounier,	R.,	 Lantier,	 L.,	 Leclerc,	 J.,	Sotiropoulos,	A.,	Foretz,	M.,	and	Viollet,	B.	 (2011).	Antagonistic	
control	of	muscle	cell	size	by	AMPK	and	mTORC1.	Cell	cycle	(Georgetown,	Tex	10,	2640-2646.	
Mounier,	R.,	Lantier,	L.,	Leclerc,	J.,	Sotiropoulos,	A.,	Pende,	M.,	Daegelen,	D.,	Sakamoto,	K.,	Foretz,	
M.,	 and	 Viollet,	 B.	 (2009).	 Important	 role	 for	 AMPKalpha1	 in	 limiting	 skeletal	 muscle	 cell	
hypertrophy.	 FASEB	 journal	 :	 official	 publication	 of	 the	 Federation	 of	 American	 Societies	 for	
Experimental	Biology	23,	2264-2273.	
Mounier,	 R.,	 Theret,	 M.,	 Arnold,	 L.,	 Cuvellier,	 S.,	 Bultot,	 L.,	 Goransson,	 O.,	 Sanz,	 N.,	 Ferry,	 A.,	
Sakamoto,	K.,	Foretz,	M.,	et	al.	(2013).	AMPKalpha1	Regulates	Macrophage	Skewing	at	the	Time	of	
Resolution	of	Inflammation	during	Skeletal	Muscle	Regeneration.	Cell	metabolism	18,	251-264.	
Mounier,	R.,	Theret,	M.,	Lantier,	L.,	Foretz,	M.,	and	Viollet,	B.	 (2015).	Expanding	roles	 for	AMPK	 in	
skeletal	muscle	plasticity.	Trends	Endocrinol	Metab	26,	275-286.	
Murray,	P.J.,	Allen,	J.E.,	Biswas,	S.K.,	Fisher,	E.A.,	Gilroy,	D.W.,	Goerdt,	S.,	Gordon,	S.,	Hamilton,	J.A.,	
Ivashkiv,	L.B.,	Lawrence,	T.,	et	al.	(2014).	Macrophage	activation	and	polarization:	nomenclature	and	
experimental	guidelines.	Immunity	41,	14-20.	
O'Neill,	L.A.,	Kishton,	R.J.,	and	Rathmell,	J.	(2016).	A	guide	to	immunometabolism	for	immunologists.	
Nat	Rev	Immunol	16,	553-565.	
Park,	S.Y.,	Lee,	S.W.,	Lee,	S.Y.,	Hong,	K.W.,	Bae,	S.S.,	Kim,	K.,	and	Kim,	C.D.	(2017).	SIRT1/Adenosine	
Monophosphate-Activated	Protein	Kinase	alpha	Signaling	Enhances	Macrophage	Polarization	 to	an	
Anti-inflammatory	Phenotype	in	Rheumatoid	Arthritis.	Front	Immunol	8,	1135.	
Pearce,	E.L.,	and	Pearce,	E.J.	(2013).	Metabolic	pathways	in	immune	cell	activation	and	quiescence.	
Immunity	38,	633-643.	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 24	
Perretti,	 M.,	 Cooper,	 D.,	 Dalli,	 J.,	 and	 Norling,	 L.V.	 (2017).	 Immune	 resolution	 mechanisms	 in	
inflammatory	arthritis.	Nat	Rev	Rheumatol	13,	87-99.	
Perretti,	M.,	and	D'Acquisto,	F.	(2009).	Annexin	A1	and	glucocorticoids	as	effectors	of	the	resolution	
of	inflammation.	Nat	Rev	Immunol	9,	62-70.	
Perretti,	 M.,	 Leroy,	 X.,	 Bland,	 E.J.,	 and	 Montero-Melendez,	 T.	 (2015).	 Resolution	 Pharmacology:	
Opportunities	for	Therapeutic	Innovation	in	Inflammation.	Trends	Pharmacol	Sci	36,	737-755.	
Rhys,	 H.I.,	 Dell'Accio,	 F.,	 Pitzalis,	 C.,	 Moore,	 A.,	 Norling,	 L.V.,	 and	 Perretti,	 M.	 (2018).	 Neutrophil	
Microvesicles	 from	 Healthy	 Control	 and	 Rheumatoid	 Arthritis	 Patients	 Prevent	 the	 Inflammatory	
Activation	of	Macrophages.	EBioMedicine	29,	60-69.	
Rodriguez-Prados,	J.C.,	Traves,	P.G.,	Cuenca,	J.,	Rico,	D.,	Aragones,	J.,	Martin-Sanz,	P.,	Cascante,	M.,	
and	Bosca,	L.	(2010).	Substrate	fate	in	activated	macrophages:	a	comparison	between	innate,	classic,	
and	alternative	activation.	J	Immunol	185,	605-614.	
Saclier,	M.,	Cuvellier,	S.,	Magnan,	M.,	Mounier,	R.,	and	Chazaud,	B.	(2013a).	Monocyte/macrophage	
interactions	 with	myogenic	 precursor	 cells	 during	 skeletal	 muscle	 regeneration.	 The	 FEBS	 journal	
280,	4118-4130.	
Saclier,	 M.,	 Yacoub-Youssef,	 H.,	 Mackey,	 A.L.,	 Arnold,	 L.,	 Ardjoune,	 H.,	 Magnan,	 M.,	 Sailhan,	 F.,	
Chelly,	J.,	Pavlath,	G.K.,	Mounier,	R.,	et	al.	(2013b).	Differentially	activated	macrophages	orchestrate	
myogenic	precursor	cell	fate	during	human	skeletal	muscle	regeneration.	Stem	Cells	31,	384-396.	
Scannell,	M.,	 Flanagan,	M.B.,	 deStefani,	 A.,	Wynne,	 K.J.,	 Cagney,	 G.,	 Godson,	 C.,	 and	Maderna,	 P.	
(2007).	Annexin-1	and	peptide	derivatives	are	released	by	apoptotic	cells	and	stimulate	phagocytosis	
of	apoptotic	neutrophils	by	macrophages.	J	Immunol	178,	4595-4605.	
Serhan,	 C.N.	 (2014).	 Pro-resolving	 lipid	mediators	 are	 leads	 for	 resolution	physiology.	Nature	 510,	
92-101.	
Serhan,	C.N.,	and	Savill,	J.	(2005).	Resolution	of	inflammation:	the	beginning	programs	the	end.	Nat	
Immunol	6,	1191-1197.	
Solito,	E.,	Kamal,	A.,	Russo-Marie,	F.,	Buckingham,	J.C.,	Marullo,	S.,	and	Perretti,	M.	(2003).	A	novel	
calcium-dependent	proapoptotic	effect	of	annexin	1	on	human	neutrophils.	FASEB	J	17,	1544-1546.	
Tabas,	 I.,	 and	 Glass,	 C.K.	 (2013).	 Anti-inflammatory	 therapy	 in	 chronic	 disease:	 challenges	 and	
opportunities.	Science	339,	166-172.	
Tannahill,	G.M.,	Curtis,	A.M.,	Adamik,	J.,	Palsson-McDermott,	E.M.,	McGettrick,	A.F.,	Goel,	G.,	Frezza,	
C.,	Bernard,	N.J.,	Kelly,	B.,	Foley,	N.H.,	et	al.	(2013).	Succinate	is	an	inflammatory	signal	that	induces	
IL-1beta	through	HIF-1alpha.	Nature	496,	238-242.	
Theret,	M.,	Gsaier,	L.,	Schaffer,	B.,	Juban,	G.,	Ben	Larbi,	S.,	Weiss-Gayet,	M.,	Bultot,	L.,	Collodet,	C.,	
Foretz,	M.,	Desplanches,	D.,	et	al.	(2017).	AMPKalpha1-LDH	pathway	regulates	muscle	stem	cell	self-
renewal	by	controlling	metabolic	homeostasis.	Embo	J	36,	1946-1962.	
Troidl,	 C.,	Mollmann,	 H.,	 Nef,	 H.,	Masseli,	 F.,	 Voss,	 S.,	 Szardien,	 S.,	Willmer,	M.,	 Rolf,	 A.,	 Rixe,	 J.,	
Troidl,	 K.,	 et	 al.	 (2009).	 Classically	 and	 alternatively	 activated	 macrophages	 contribute	 to	 tissue	
remodelling	after	myocardial	infarction.	J	Cell	Mol	Med	13,	3485-3496.	
Van	den	Bossche,	 J.,	O'Neill,	 L.A.,	and	Menon,	D.	 (2017).	Macrophage	 Immunometabolism:	Where	
Are	We	(Going)?	Trends	Immunol	38,	395-406.	
Varga,	 T.,	 Mounier,	 R.,	 Gogolak,	 P.,	 Poliska,	 S.,	 Chazaud,	 B.,	 and	 Nagy,	 L.	 (2013).	 Tissue	 LyC6-	
macrophages	are	generated	in	the	absence	of	circulating	LyC6-	monocytes	and	Nur77	in	a	model	of	
muscle	regeneration.	J	Immunol	191,	5695-5701.	
Varga,	 T.,	 Mounier,	 R.,	 Horvath,	 A.,	 Cuvellier,	 S.,	 Dumont,	 F.,	 Poliska,	 S.,	 Ardjoune,	 H.,	 Juban,	 G.,	
Nagy,	L.,	and	Chazaud,	B.	(2016a).	Highly	Dynamic	Transcriptional	Signature	of	Distinct	Macrophage	
Subsets	during	Sterile	Inflammation,	Resolution,	and	Tissue	Repair.	J	Immunol	196,	4771-4782.	
Varga,	T.,	Mounier,	R.,	Patsalos,	A.,	Gogolak,	P.,	Peloquin,	M.,	Horvath,	A.,	Pap,	A.,	Daniel,	B.,	Nagy,	
G.,	 Pintye,	 E.,	 et	 al.	 (2016b).	 Macrophage	 PPARgamma,	 a	 Lipid	 Activated	 Transcription	 Factor	
Controls	the	Growth	Factor	GDF3	and	Skeletal	Muscle	Regeneration.	Immunity	45,	1038-1051.	
	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
Wild-Type AnxA1-/- Fpr2/3-/-
CTX
Days 0
Analysis
7
Analysis
28
Analysis
A
C
D E F
G H
B
Figure 1
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
WT
 / W
T
GF
P /
 G
FP
WT
 / G
FP
GF
P /
 W
T
GF
P /
 A
nx
A1
-/-
0.1
1
10
100
G
FP
+
m
on
oc
yt
es
(%
 o
f C
D
11
5+
ce
lls
)
A
B
WT / WT GFP / GFP
WT / GFP GFP / AnxA1-/- GFP / WT
C
CX3CR1
C
D
1
1
5
D E
X-rays CTX
Analysis
Days 0 28-40
Analysis
BMT
Non-GFP
BM
CX3CR1-GFP
Blood
check
-7
Wild-Type
AnxA1-/-
Figure 2
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
A B
C D
H
E F
G
MHCII intensity
C
ou
nt
s
Vehicle
hrANXA1
CD206 intensity
C
ou
nt
s
Vehicle
hrANXA1
Figure 3
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
Wild-Type Fpr2/3-/-
0.0
0.5
1.0
1.5
2.0
pA
M
PK
:A
M
PK
 ra
tio
(n
or
m
al
is
ed
 to
 v
eh
ic
le
) Veh
hrANXA1*
0
1
2
3
4
pA
M
PK
:A
M
PK
 ra
tio
(n
or
m
al
is
ed
 to
 v
eh
ic
le
)
* **
Veh 30' 60'ANXA1
WRW4 -
Veh 30' 60'
- - + + +
Veh 10' 30' 60'
0.0
0.5
1.0
1.5
2.0
pA
C
C
:A
C
C
 ra
tio
(n
or
m
al
is
ed
 to
 v
eh
ic
le
)
*
ANXA1
Veh 10' 30' 60'
0.0
0.5
1.0
1.5
2.0
2.5
pA
M
PK
:A
M
PK
 ra
tio
(n
or
m
al
is
ed
 to
 v
eh
ic
le
)
**
*
ANXA1
A B C
D
ANXA1
FPR2
CaMK
AMPK
ACC
E F
pCaMK
pAMPKα1
AMPKα1
pACC
ACC
β-actin
Veh 10' 30' 60'
ANXA1
pAMPKα1
AMPKα1
Veh ANXA130'
ANXA1
60'
WRW4
Veh ANXA130'
ANXA1
60' pAMPKα1
AMPKα1
Veh ANXA160'
Wild-Type
Veh ANXA160'
Fpr2/3-/-
Figure 4
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
A B
C D E
β-actin
AMPKα1
iNOS CCL3 TGFβ1 CD163 CD206
F G
H I
Medium
Transfert
Myoblast
fusion
72h
Wild-Type AMPKa1-/-
C
on
tro
l
+ 
hr
A
N
X
A
1
Macrophages Myoblasts
Figure 5
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
A B
DAPI Ly6G ANXA1 Merged
2nd/
Isotype
Day 0
Day 1
Day 2
Day 7
Day 14
DAPI F4/80 ANXA1 Merged
C
Supplementary Figure 1
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
DAPI F4/80 FPR2 Merged
2nd/
Isotype
Day 2
Day 7
Day 14
BA
Supplementary Figure 2
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
AB
C
F4/80
Ly
6C
/G
AnxA1-/-Wild-Type Fpr2/3-/-
AnxA1-/-Wild-Type
Supplementary Figure 3
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
BA C D
M0
M1
M2
2nd only
FPR2/ALX intensity
C
el
l F
re
qu
en
cy
Supplementary Figure 4
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
